11 Best Performing Dow Stocks So Far in 2025

7. Amgen Inc. (NASDAQ:AMGN)

Year-to-date return as of February 14: 12.30%

Amgen (NASDAQ:AMGN) creates and distributes a range of human pharmaceuticals, including treatments for conditions like cancer, psoriasis, osteoporosis, arthritis, and cardiovascular disorders. Since the start of 2025 through February 14, the stock has surged by over 12%, which makes it one of the best performing stocks.

A biopharmaceutical business with a portfolio of popular medications, Amgen (NASDAQ:AMGN) is highly profitable. Sales of its flagship medication, Repatha, which lowers cholesterol, are rising as a result of research proving the dangers of any cholesterol level.

It has a robust oncology franchise as well. MariTide, its weight-loss medication, may revolutionize the market. MariTide provides the ease of a once-monthly dose, which is a significant benefit in the rapidly expanding obesity medication industry, in contrast to Ozempic and Mounjaro, which call for weekly injections. Recently, the stock has surged as investors have realized this possibility. Amgen (NASDAQ:AMGN) could witness a significant increase in awareness and valuation once MariTide is released onto the market.

The company reported revenue of $33.4 billion in FY2024, up 19% due to the Horizon acquisition, and non-GAAP earnings per share of $19.84, up 6%.

Piper Sandler increased its price target of Amgen (NASDAQ:AMGN) from $310 to $329. According to the firm, the PSC Biopharma Research team recently co-hosted its Virtual TSLP Day, which included virtual fireside conversations with several businesses, including Amgen, that are focusing on thymic stromal lymphopoietin. Piper learned more about how management is considering next-generation TSLP-directed medicines and how the firm is considering ways to expand Tezspire’s use beyond severe asthma. Overall, the company still sees Tezspire by itself as a multibillion-dollar possibility in the United States and one of Amgen’s most significant long-term top-line drivers.